About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Cd79atm3(cre/ERT2)Reth
targeted mutation 3, Michael Reth
MGI:5568505
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+
Cd79atm3(cre/ERT2)Reth/Cd79a+ 		involves: 129S6/SvEvTac * BALB/c MGI:5568507
cn2
 		Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+
Cd79atm3(cre/ERT2)Reth/Cd79a+
Tg(BCL2)22Wehi/0 		involves: 129S6/SvEvTac * BALB/c * C57BL/6JWehi * SJL/JWehi MGI:5568509


Genotype
MGI:5568507
cn1
Allelic
Composition		 Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+
Cd79atm3(cre/ERT2)Reth/Cd79a+
Genetic
Background		 involves: 129S6/SvEvTac * BALB/c
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd79atm3(cre/ERT2)Reth mutation (2 available); any Cd79a mutation (24 available)
Gt(ROSA)26Sortm1(ETV6/SYK)Hjum mutation (0 available); any Gt(ROSA)26Sor mutation (993 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
increased B cell apoptosis ( J:208904 )
• 20-fold 7 days after tamoxifen-treatment
increased B cell proliferation ( J:208904 )
• in tamoxifen-treated mice
• however, LPS-induced proliferation is normal and treatment with Syk-specific inhibitor R406 abolishes proliferation
enlarged spleen ( J:208904 )
• 3 and 7 days after tamoxifen treatment
• however, spleen size is restored by 14 days post-induction
abnormal plasma cell differentiation ( J:208904 )
• B cells from tamoxifen-treated mice undergo terminal differentiation into short-lived B cells
increased B cell number ( J:208904 )
• CD19+ B cells in tamoxifen-treated mice
• however, the increased numbers is followed by a decrease
increased IgM level ( J:208904 )
• 20-fold 7 days after tamoxifen-treatment
abnormal circulating chemokine level ( J:208904 )
• increased serum levels of monocyte chemoattractant protein-1, peaking at days 3 to 5 after tamoxifen-treatment
increased circulating interferon-gamma level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment
increased circulating interleukin-10 level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment
increased circulating interleukin-6 level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment
increased circulating tumor necrosis factor level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment
enlarged lymph nodes ( J:208904 )
• 3 and 7 days after tamoxifen treatment
increased interferon-gamma secretion ( J:208904 )
• in follicular B cells after tamoxifen-treatment
increased interleukin-10 secretion ( J:208904 )
• in follicular B cells after tamoxifen-treatment
increased tumor necrosis factor secretion ( J:208904 )
• in follicular B cells after tamoxifen-treatment

homeostasis/metabolism
abnormal circulating chemokine level ( J:208904 )
• increased serum levels of monocyte chemoattractant protein-1, peaking at days 3 to 5 after tamoxifen-treatment
increased circulating interferon-gamma level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment
increased circulating interleukin-10 level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment
increased circulating interleukin-6 level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment
increased circulating tumor necrosis factor level ( J:208904 )
• peaking at days 3 to 5 after tamoxifen-treatment

cellular
increased B cell apoptosis ( J:208904 )
• 20-fold 7 days after tamoxifen-treatment
increased B cell proliferation ( J:208904 )
• in tamoxifen-treated mice
• however, LPS-induced proliferation is normal and treatment with Syk-specific inhibitor R406 abolishes proliferation

hematopoietic system
increased B cell apoptosis ( J:208904 )
• 20-fold 7 days after tamoxifen-treatment
increased B cell proliferation ( J:208904 )
• in tamoxifen-treated mice
• however, LPS-induced proliferation is normal and treatment with Syk-specific inhibitor R406 abolishes proliferation
enlarged spleen ( J:208904 )
• 3 and 7 days after tamoxifen treatment
• however, spleen size is restored by 14 days post-induction
abnormal plasma cell differentiation ( J:208904 )
• B cells from tamoxifen-treated mice undergo terminal differentiation into short-lived B cells
increased B cell number ( J:208904 )
• CD19+ B cells in tamoxifen-treated mice
• however, the increased numbers is followed by a decrease
increased IgM level ( J:208904 )
• 20-fold 7 days after tamoxifen-treatment

growth/size/body
enlarged spleen ( J:208904 )
• 3 and 7 days after tamoxifen treatment
• however, spleen size is restored by 14 days post-induction




Genotype
MGI:5568509
cn2
Allelic
Composition		 Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+
Cd79atm3(cre/ERT2)Reth/Cd79a+
Tg(BCL2)22Wehi/0
Genetic
Background		 involves: 129S6/SvEvTac * BALB/c * C57BL/6JWehi * SJL/JWehi
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd79atm3(cre/ERT2)Reth mutation (2 available); any Cd79a mutation (24 available)
Gt(ROSA)26Sortm1(ETV6/SYK)Hjum mutation (0 available); any Gt(ROSA)26Sor mutation (993 available)
Tg(BCL2)22Wehi mutation (2 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
enlarged spleen ( J:208904 )
• severe after tamoxifen treatment
abnormal plasma cell differentiation ( J:208904 )
• B cells from tamoxifen-treated mice undergo terminal differentiation into short-lived B cells
abnormal B cell physiology ( J:208904 )
• prolonged survival and reduced apoptosis of plasma cells after tamoxifen treatment
enlarged lymph nodes ( J:208904 )
• severe after tamoxifen treatment

hematopoietic system
enlarged spleen ( J:208904 )
• severe after tamoxifen treatment
abnormal plasma cell differentiation ( J:208904 )
• B cells from tamoxifen-treated mice undergo terminal differentiation into short-lived B cells
abnormal B cell physiology ( J:208904 )
• prolonged survival and reduced apoptosis of plasma cells after tamoxifen treatment

growth/size/body
enlarged spleen ( J:208904 )
• severe after tamoxifen treatment




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory